News
Events
Research
Ways to help
About us
Contact Us
DONATE NOW
EVENTS
ANNUAL BALL
CONTACT US
SIGN UP TO NEWSLETTER
Jun 2014
Predicting MS in children
Oct 2014
Three new Incubator Grants announced
Dec 2014
2015 Funding announced
Mar 2015
Investigating new treatment options
Oct 2015
Progress in MS Research Conference
Feb 2016
2016 Round of Funding
Feb 2014
New projects being funded
Feb 2014
Breakthrough study shows great promise

Research fellow studying ways
to increase myelin growth

 

A nerve growth factor, known as brain-derived neurotrophic factor (BDNF), has been found to promote myelination by activating different receptors on the surface of myelin-producing cells (known as oligodendrocytes). Working with Dr Simon Murray and Dr Junhua Xiao at the University of Melbourne, Dr Jessica Fletcher is undertaking a postdoctoral fellowship supported by the Trish MS Research Foundation, aiming to investigate the effects when BDNF is switched on inside myelin-producing oligodendrocytes.

BDNF is known to function alongside a number of other specific chemicals (called Erk1/2) in a chemical ‘pathway’ within cells.  Studying mice with MS-like illness, Dr Fletcher is testing whether the Erk chemicals in this pathway can work together, following the activation of BDNF, to increase myelin production.

This project is the first step towards identifying whether the BDNF pathway may be a useful target for developing new treatments to promote myelin repair and halt MS disease progression. It is crucial to identify potential new treatment targets that can promote myelin repair, prevent nerve damage and halt MS disease progression.

Over the first half of her fellowship in 2015 and 2016 Dr Fletcher has made excellent progress. Dr Fletcher has concentrated on the role of molecules which are switched on in response to activation of BDNF in myelin producing cells, known as Erk1/2. Dr Fletcher used animal models of an MS-like illness to show that activation of Erk1/2 was important for natural repair of myelin and further that increasing the signalling through the Erk1/2 pathway promoted the myelin repair.

In a separate series of experiments, Dr Fletcher has also started to determine the underlying mechanisms used by Erk1/2 at a molecular level, to try to understand the way that myelin repair is regulated.

This work, together with the work that her colleagues in the laboratory are doing, is important since identifying the many different molecules that are involved in myelin repair will provide new targets for the treatment for progressive MS, to promote myelin repair, prevent nerve damage and halt MS disease progression.

In a validation of the importance of her findings, Dr Fletcher has already presented her results at a number of national and international conferences throughout 2015 and 2016. We await her formally published findings with great interest.

Trish Foundation & MS Research Australia Working together to find a cure for MS
Copyright © Trish Multiple Sclerosis Research Foundation. All rights reserved.